# 510(k) SUBSTANTIAL EQUIVALENCE DETERMINATION DECISION SUMMARY ASSAY ONLY TEMPLATE

A. 510(k) Number: k082091   
B. Purpose for Submission: New Device   
C. Measurand: Lymphocyte Subsets $\mathrm { C D 3 + C D 4 + }$ , $\mathrm { C D 3 + C D 8 + }$   
D. Type of Test: Quantitative   
E. Applicant: ReaMetrix, Inc.   
F. Proprietary and Established Names: Dry Tri T-STAT (CD3/CD4/CD8) Reagent

# G. Regulatory Information:

2. Classification: Class II

3. Product code: GKZ, Counter differential cell

4. Panel: Hematology (81)

# H. Intended Use:

1. Intended use(s): The Dry Tri T-STAT (CD3/CD4/CD8) Reagent is a three-color immunofluorescence stain for the labeling and identification of helper/inducer $\left( \mathrm { C D 3 + C D 4 + } \right)$ and cytotoxic/suppressor $\left( \mathrm { C D 3 + C D 8 + } \right)$ T lymphocytes combined with a precise number of fluorescent counting beads to provide absolute $\mathrm { C D 4 + }$ and $\mathrm { C D 8 + }$ T-Cell counts. This reagent is intended to be used for flow cytometric analysis of erythrocyte-lysed human whole blood.

2. Indication(s) for use:

The Dry Tri T-STAT (CD3/CD4/CD8) Reagent is intended for in vitro diagnostic use, is a three-color immunofluorescence stain for the labeling and identification of helper/inducer $\mathrm { ( C D 3 + C D 4 + ) }$ ) and cytotoxic/suppressor $( \mathrm { C D 3 + C D 8 + } )$ ) T lymphocytes combined with a precise number of fluorescent counting beads to provide absolute $\mathrm { C D 4 + }$ and $\mathrm { C D 8 + }$ T-Cell counts. This reagent is intended to be used for flow cytometric analysis of erythrocyte-lysed human whole blood. The DryTri T-STAT Reagent can be used to monitor forms of immunodeficiency.

3. Special conditions for use statement(s): For prescription use only.

4. Special instrument requirements: Becton Dickinson FACScan, Becton Dickinson FACSCalibur and Beckman Coulter EPICS XL-MCL

# I. Device Description:

The Dry Tri T-STAT (CD3/CD4/CD8) Reagent is formulated in buffered saline with sodium azide and stabilizers. It contains ATTO 488 – labeled CD4 monoclonal antibody, clone RPAT4; phycoerythrin (PE) – labeled CD8 monoclonal antibody, clone LT8; and PE-DY- 649 – labeled CD3 monoclonal antibody, clone UCHT1. The specificities of the monoclonal antibodies used in the Dry Tri T-STAT (CD3/CD4/CD8) were confirmed by the Human Leukocyte Differentiation Antigens (HLDA) Workshops (9). A precise number of fluorescent counting beads are included in the Dry Tri T-STAT reagent to allow single-platform determination of absolute $\mathrm { C D 4 + }$ and $\mathrm { C D 8 + }$ T-cell counts. The Dry-Tri T-STAT reagent is provided in dried form and dispensed in flow cytometer compatible sample tubes with each tube containing one ready-to-use test. Fifty (50) tests are supplied in each Dry Tri T-STAT (CD3/CD4/CD8) package.

# J. Substantial Equivalence Information:

1. Predicate device name(s): Becton Dickinson TriTEST™ reagent CD4 FITC/CD8 PE/CD3 PerCP; & TruCount Absolute counting tubes Beckman Coulter CYTO-STAT $^ \mathrm { \textregistered }$ CD45-FITC/CD4-PE/CD8-ECD/CD3-PC5 TetraCHROME reagent   
2. Predicate K number(s): k971205 k030408   
3. Comparison with predicate:

<table><tr><td colspan="4" rowspan="1">Similarities</td></tr><tr><td colspan="1" rowspan="1">Item</td><td colspan="1" rowspan="1">Dry Tri T-STATreagent</td><td colspan="1" rowspan="1">Tri TEST reagent</td><td colspan="1" rowspan="1">CYTO-STATTetraCHROMEreagent</td></tr><tr><td colspan="1" rowspan="1">Indication for use</td><td colspan="1" rowspan="1">Enumeration ofCD4+and CD8+ T-cells</td><td colspan="1" rowspan="1">Same</td><td colspan="1" rowspan="1">Same</td></tr><tr><td colspan="1" rowspan="1">Flow cytometer requirements</td><td colspan="1" rowspan="1">488nm excitationlaser with sidescatter, forwardscatter, 3fluorescencechannels</td><td colspan="1" rowspan="1">Same</td><td colspan="1" rowspan="1">Same</td></tr><tr><td colspan="1" rowspan="1">Analysis Reagent</td><td colspan="1" rowspan="1">3-colorfluorochromereagent</td><td colspan="1" rowspan="1">3-colorfluorochromereagent</td><td colspan="1" rowspan="1">4-colorfluorochromereagent</td></tr><tr><td colspan="1" rowspan="1">Data analysis</td><td colspan="1" rowspan="1">Manual analysisusing customercreated protocolsaccording toPackage Insert</td><td colspan="1" rowspan="1">Same</td><td colspan="1" rowspan="1">Same</td></tr><tr><td colspan="4" rowspan="1">Differences</td></tr><tr><td colspan="1" rowspan="1">Item</td><td colspan="1" rowspan="1">Tri T-STATreagent</td><td colspan="1" rowspan="1">Tri TEST reagent</td><td colspan="1" rowspan="1">CYTO-STATTetraCHROMEreagent</td></tr><tr><td colspan="1" rowspan="1">CD4 detection reagent</td><td colspan="1" rowspan="1">Monoclonalantibody RPA-T4conjugated to Atto488</td><td colspan="1" rowspan="1">Monoclonalantibody SK3conjugated to PE</td><td colspan="1" rowspan="1">MonoclonalantibodySFC121T4D11conjugated tophycoerythrin (PE)</td></tr><tr><td colspan="1" rowspan="1">CD8 detection reagent</td><td colspan="1" rowspan="1">Monoclonalantibody LT8conjugated to PE</td><td colspan="1" rowspan="1">Monoclonalantibody SK1conjugated to PE</td><td colspan="1" rowspan="1">MonoclonalantibodySFC121Thy2D3conjugated to PE-Texas Red® -X</td></tr><tr><td colspan="1" rowspan="1">CD3 detection reagent</td><td colspan="1" rowspan="1">Monoclonalantibody UCHT1conjugated to PE-Dyomics 649</td><td colspan="1" rowspan="1">Monoclonalantibody SK7conjugated toPerCP</td><td colspan="1" rowspan="1">Monoclonalantibody UCHT1conjugated to PE-Cy5}$</td></tr><tr><td colspan="1" rowspan="1">Analysis reagent</td><td colspan="1" rowspan="1">ReaCountfluorescent beads</td><td colspan="1" rowspan="1">TruCount tubes</td><td colspan="1" rowspan="1">Flow-Countfluorospheres</td></tr><tr><td colspan="1" rowspan="1">Sample age, pre-processing</td><td colspan="1" rowspan="1">Potassium EDTA,blood processedwithin 24 hr draw</td><td colspan="1" rowspan="1">Potassium EDTA,blood processedwithin 48 hr draw</td><td colspan="1" rowspan="1">Potassium EDTA,blood processedwithin 72 hr draw</td></tr></table>

# K. Standard/Guidance Document Referenced (if applicable):

H20-A Reference Leukocyte Differential Count (Proportional) and Evaluation of Instrument Methods, Approved Standard, CLSI

H42-A Clinical Applications of Flow Cytometry: Quality Assurance and Immunophenotyping of Lymphocytes, Approved Guideline, CLSI

# L. Test Principle:

The Dry Tri T-STAT (CD3/CD4/CD8) reagent consists of murine monoclonal antibodies that specifically recognize the human leukocyte surface antigens, CD3, CD4, and CD8. Each of the monoclonal antibodies is labeled with a unique fluorochrome. Specific cell subsets are stained when blood is combined with the reagent and each monoclonal antibody binds to the binds to the cell determinant molecules on the cell surface. Specific cell subsets are identified when passed through a flow cytometer laser beam.

The Dry Tri T-STAT (CD3/CD4/CD8) reagent also contains a precise number of fluorescent beads. When the reagent is combined with a known volume of blood the reagent provides for the single platform determination of the absolute cell concentrations of the stained subsets. The volume of sample analyzed can be determined by multiplication of the total sample volume by the fraction of total beads that were detected during the analysis.

# M. Performance Characteristics (if/when applicable):

1. Analytical performance:

a. Precision/Reproducibility:

The reproducibility of measurement was determined for three concentrations of $\mathrm { C D 3 + C D 4 + }$ and $\mathrm { C D 3 + C D 8 + }$ T-cells counts analyzed in replicates of ten. The results are tabulated below.

<table><tr><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>Level</td><td rowspan=1 colspan=1>Mean(cells/μL)</td><td rowspan=1 colspan=1>SD</td><td rowspan=1 colspan=1>%CV</td></tr><tr><td rowspan=3 colspan=1>CD3+CD4+T-cells</td><td rowspan=1 colspan=1>Low</td><td rowspan=1 colspan=1>29</td><td rowspan=1 colspan=1>1.7</td><td rowspan=1 colspan=1>6</td></tr><tr><td rowspan=1 colspan=1>Medium</td><td rowspan=1 colspan=1>607</td><td rowspan=1 colspan=1>23.6</td><td rowspan=1 colspan=1>3.9</td></tr><tr><td rowspan=1 colspan=1>High</td><td rowspan=1 colspan=1>1173</td><td rowspan=1 colspan=1>66.3</td><td rowspan=1 colspan=1>5.7</td></tr><tr><td rowspan=3 colspan=1>CD3+CD8+T-cells</td><td rowspan=1 colspan=1>Low</td><td rowspan=1 colspan=1>655</td><td rowspan=1 colspan=1>45.1</td><td rowspan=1 colspan=1>6.9</td></tr><tr><td rowspan=1 colspan=1>Medium</td><td rowspan=1 colspan=1>770</td><td rowspan=1 colspan=1>37.1</td><td rowspan=1 colspan=1>4.8</td></tr><tr><td rowspan=1 colspan=1>High</td><td rowspan=1 colspan=1>1557</td><td rowspan=1 colspan=1>30</td><td rowspan=1 colspan=1>1.9</td></tr></table>

$b$ . Linearity/assay reportable range:

Assay linearity was determined by testing six point dilution series, 64-1680 $\mathrm { C D 3 + C D 4 + }$ T-cells $\mu \mathrm { L }$ and $3 2 { \mathrm { - } } 1 6 4 0 \mathrm { C D } 3 { \mathrm { + } } \mathrm { C D } 8 { \mathrm { + } } \mathrm { T } { \mathrm { - } } \mathrm { c e l l s } / { \mu \mathrm { L } }$ . The measurement at each level was performed in triplicate. The assay was determined to be linear for $\mathrm { C D 3 + C D 4 + }$ and $\mathrm { C D 3 + C D 8 + }$ T-cells with correlation coefficients $( { \mathrm { r } } ^ { 2 } )$ of 0.995 and 0.999, respectively.

The two dilution series spanned the specified reportable ranges of 65-1500 $\mathrm { C D 3 + C D 4 + }$ T-cells $\mu \mathrm { L }$ and 40-1500 CD3+CD8+ T-cells $\mu \mathrm { L }$ .

c. Traceability, Stability, Expected values (controls, calibrators, or methods): Reagent stability was tested by staining control material cells over 52 weeks. The mean fluorescence intensity (MFI) of the cells was measured and tracked, in triplicate. The data presented demonstrated the relative MFI of the CD3- PE-Dyomics 649, CD4-Atto488 and CD8-PE conjugates were not diminished of the 52 week period.

d. Detection limit: Not applicable.

e. Analytical specificity: Not applicable.

f. Assay cut-off: Not applicable.

2. Comparison studies:

a. Method comparison with predicate device: The absolute $\mathrm { C D 3 + C D 4 + }$ and $\mathrm { C D 3 + C D 8 + }$ T-cells concentrations for 291 blood samples (both HIV positive and negative) at 4 sites were determined using the Dry Tri T-STAT (CD3/CD4/CD8) reagent and compared to those values determined using the predicate reagents. Regression analysis reported in the table below indicates substantial equivalence.

<table><tr><td rowspan=1 colspan=1>Parameter</td><td rowspan=1 colspan=1>Slope</td><td rowspan=1 colspan=1>Y-Intercept</td><td rowspan=1 colspan=1>$r^2}$</td></tr><tr><td rowspan=1 colspan=1>Site 1 (n=45)</td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1></td></tr><tr><td rowspan=1 colspan=1>CD3+CD4+ T-cells</td><td rowspan=1 colspan=1>0.87</td><td rowspan=1 colspan=1>-3.28</td><td rowspan=1 colspan=1>0.989</td></tr><tr><td rowspan=1 colspan=1>CD3+CD8+ T-cells</td><td rowspan=1 colspan=1>0.89</td><td rowspan=1 colspan=1>35.0</td><td rowspan=1 colspan=1>0.962</td></tr><tr><td rowspan=1 colspan=1>Site 2 (n=96)</td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1></td></tr><tr><td rowspan=1 colspan=1>CD3+CD4+ T-cells</td><td rowspan=1 colspan=1>0.97</td><td rowspan=1 colspan=1>-8.47</td><td rowspan=1 colspan=1>0.933</td></tr><tr><td rowspan=1 colspan=1>CD3+CD8+ T-cells</td><td rowspan=1 colspan=1>1.04</td><td rowspan=1 colspan=1>-58.3</td><td rowspan=1 colspan=1>0.912</td></tr><tr><td rowspan=1 colspan=1>Site 3 (n=100)</td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1></td></tr><tr><td rowspan=1 colspan=1>CD3+CD4+ T-cell</td><td rowspan=1 colspan=1>0.98</td><td rowspan=1 colspan=1>5.85</td><td rowspan=1 colspan=1>0.915</td></tr><tr><td rowspan=1 colspan=1>Site 4 (n=50)</td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1></td></tr><tr><td rowspan=1 colspan=1>CD3+CD4+ T-cells</td><td rowspan=1 colspan=1>0.90</td><td rowspan=1 colspan=1>12.99</td><td rowspan=1 colspan=1>0.987</td></tr><tr><td rowspan=1 colspan=1>CD3+CD8+ T-cells</td><td rowspan=1 colspan=1>0.88</td><td rowspan=1 colspan=1>2.49</td><td rowspan=1 colspan=1>0.960</td></tr></table>

b. Matrix comparison: Not applicable.

3. Clinical studies:

a. Clinical Sensitivity: Not applicable.   
b. Clinical specificity: Not applicable.   
c. Other clinical supportive data (when a. and b. are not applicable): Not applicable.

4. Clinical cut-off: Not applicable.

5. Expected values/Reference range:

The absolute $\mathrm { C D 4 + }$ and $\mathrm { C D 8 + }$ T lymphocyte concentrations were measured for a normal population of adults in southern India, unselected for age or gender ranging from 21 to 80 years old, using the Dry Tri T-STAT (CD3/CD4/CD8) reagent. Values obtained from this diverse population are displayed below and consistent with the reported normal range.

<table><tr><td rowspan=1 colspan=1>T-Cell Subset</td><td rowspan=1 colspan=1>n</td><td rowspan=1 colspan=1>Minimum(cells/μL)</td><td rowspan=1 colspan=1>Maximum(cells/μL)</td><td rowspan=1 colspan=1>Mean±SD(cells/μL)</td></tr><tr><td rowspan=1 colspan=1>CD3+CD4+ T-cells</td><td rowspan=1 colspan=1>112</td><td rowspan=1 colspan=1>457</td><td rowspan=1 colspan=1>2076</td><td rowspan=1 colspan=1>995± 298</td></tr><tr><td rowspan=1 colspan=1>CD3+CD4+ T-cells</td><td rowspan=1 colspan=1>112</td><td rowspan=1 colspan=1>196</td><td rowspan=1 colspan=1>1402</td><td rowspan=1 colspan=1>634±3300</td></tr></table>

It is recommended that each laboratory establish its own expected values from the local population of donors.

# N. Proposed Labeling:

The labeling is sufficient and it satisfies the requirements of 21 CFR Part 809.10.

# O. Conclusion:

The submitted information in this premarket notification is complete and supports a substantial equivalence decision.